•
AB
ABEO
Abeona Therapeutics Inc. Common Stock
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
287.76M
Volume
1.19M
52W High
$7.54
52W Low
$3.93
Open
$5.31
Prev Close
$5.31
Day Range
5.19 - 5.38
About Abeona Therapeutics Inc. Common Stock
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Latest News
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Dec 31
Here's Why Abeona Therapeutics Popped Higher Today
The Motley Fool•Nov 12
Trends & Growth Strategies in the $13.5 Billion Cancer Gene Therapy Market 2025-2030 - Advancements CRISPR and CAR-T Solutions Propel Industry Growth
GlobeNewswire Inc.•Sep 2
AscellaHealth Ranks No. 535 on the 2025 Inc. 5000 List of America’s Fastest-Growing Private Companies
GlobeNewswire Inc.•Aug 12
US FDA Orphan Drug Rare Disease Market Clinical Trials Drug Sales Insight 2030
GlobeNewswire Inc.•May 14
U.S. FDA Approves ZEVASKYNâ„¢ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
GlobeNewswire Inc.•Apr 29
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight
GlobeNewswire Inc.•Feb 21
Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI
GlobeNewswire Inc.•Jan 2